Who are GP40321's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aripiprazole tablet, Risperdal,reminyl, placebo with Clozapine, Aripiprazole; Quetiapine, Mescaline sodium enteric-coated tablets, Any FDA approved antipsychotic agent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gp40321.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

GP40321 — Competitive Intelligence Brief

GP40321 (GP40321) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor antagonist. Area: Psychiatry.

phase 3 Serotonin receptor antagonist 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

GP40321 (GP40321) — Geropharm. GP40321 is a small molecule that targets the serotonin receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GP40321 TARGET	GP40321	Geropharm	phase 3	Serotonin receptor antagonist	5-HT2A receptor
Aripiprazole tablet	Aripiprazole tablet	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist)
Risperdal,reminyl	Risperdal,reminyl	Jinan Mental Hospital	marketed	Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl)	Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
placebo with Clozapine	placebo with Clozapine	Shanghai Mental Health Center	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Aripiprazole; Quetiapine	Aripiprazole; Quetiapine	Taichung Veterans General Hospital	marketed	Atypical antipsychotic combination	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Mescaline sodium enteric-coated tablets	Mescaline sodium enteric-coated tablets	Xiangya Hospital of Central South University	marketed	Serotonin receptor agonist; psychedelic	5-HT2A receptor (primary); non-selective serotonin receptors
Any FDA approved antipsychotic agent	Any FDA approved antipsychotic agent	Vanguard Research Group	marketed	Antipsychotic (dopamine antagonist)	Dopamine D2 receptor (primary); serotonin 5-HT2A receptor and others (varies by agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin receptor antagonist class)

Addpharma Inc. · 2 drugs in this class
Shire · 2 drugs in this class
Gedeon Richter Plc. · 1 drug in this class
Geropharm · 1 drug in this class
H. Lundbeck A/S · 1 drug in this class
Infan Industria Quimica Farmaceutica Nacional · 1 drug in this class
Phytopharm Consulting Brazil · 1 drug in this class
Taisho Pharmaceutical Co., Ltd. · 1 drug in this class
Aclaris Therapeutics, Inc. · 1 drug in this class
Visirna Therapeutics HK Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GP40321 — Competitive Intelligence Brief. https://druglandscape.com/ci/gp40321. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab